4.4 Article

Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma

期刊

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/17474124.2021.1915765

关键词

Cholangiocarcinoma; isocitrate dehydrogenase; ivosidenib; precision medicine

向作者/读者索取更多资源

Cholangiocarcinomas (CCAs) have poor survival outcomes with limited treatment options. Ivosidenib, a selective inhibitor of mutant IDH1, presents a promising treatment option for patients with IDH1 mutant CCA. Future studies may explore the use of this targeted agent in combination with other anticancer treatments to improve survival outcomes in advanced CCA.
Introduction: Cholangiocarcinomas (CCAs) are associated with poor survival outcomes, with limited treatment options in the unresectable or metastatic setting. A precision medicine approach to cancer treatment has revealed new therapeutic options that provide an alternative to traditional chemotherapeutic strategies. Isocitrate dehydrogenase 1 (IDH1) mutations are identified in approximately 10-15% of CCAs and may be targeted by ivosidenib, an oral selective inhibitor of mutant IDH1. Areas covered: This review will discuss the pathogenesis of IDH1 mutant CCA and the role of ivosidenib in patients with IDH1 mutant CCA. Topics to be covered include the pharmacology, safety and clinical efficacy of ivosidenib in this patient population. Expert opinion: Ivosidenib represents a promising treatment option for patients with IDH1 mutant CCA with a favorable side effect profile. Future studies will guide whether this targeted agent may be utilized in combination with other anticancer treatments to improve upon survival outcomes in advanced CCA.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据